GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Liabilities

Verici Dx (Verici Dx) Total Liabilities : $2.67 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Total Liabilities?

Verici Dx's Total Liabilities for the quarter that ended in Jun. 2023 was $2.67 Mil.

Verici Dx's quarterly Total Liabilities increased from Jun. 2022 ($1.87 Mil) to Dec. 2022 ($2.80 Mil) but then declined from Dec. 2022 ($2.80 Mil) to Jun. 2023 ($2.67 Mil).

Verici Dx's annual Total Liabilities increased from Dec. 2020 ($0.68 Mil) to Dec. 2021 ($1.80 Mil) and increased from Dec. 2021 ($1.80 Mil) to Dec. 2022 ($2.80 Mil).


Verici Dx Total Liabilities Historical Data

The historical data trend for Verici Dx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Total Liabilities Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Total Liabilities
0.68 1.80 2.80

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Total Liabilities 0.58 1.80 1.87 2.80 2.67

Verici Dx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Verici Dx's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.252+(0.544+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.80

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=14.305-11.509
=2.80

Verici Dx's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.203+(0.462+1.6653345369377E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.67

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=9.353-6.688
=2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx Total Liabilities Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines